Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier

Journal of Cellular Physiology

Volumn 195, Issue 2, 2003, Pages 210-219

  Saishin, Yoshitsugu ^a   Saishin, Yumiko ^a   Takahashi, Kyoichi ^a   Melia, Michele ^a   Vinores, Stanley A ^a   Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; MIDOSTAURIN; PHOSPHOTRANSFERASE INHIBITOR; PROSTAGLANDIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; SOMATOMEDIN C; SU 1498; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR KINASE INHIBITOR; VATALANIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; ENZYME INHIBITION; INFLAMMATION; MALE; MOUSE; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETINA DISEASE; RETINA ISCHEMIA; RETINA MACULA EDEMA; VISUAL IMPAIRMENT;

ALPROSTADIL; ANIMALS; BLOOD-RETINAL BARRIER; DINOPROSTONE; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-1; LYMPHOKINES; MALE; MICE; PROTEIN KINASE C; RETINA; RETINAL DISEASES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037401530     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.10238     Document Type: Article

References (54)

1. Adamis AP, Miller JW, Bernal M-T, D'Amico DJ, Folkman J, Yeo T-K, Yeo K-T. 1994. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445-450.
2. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen MS, Aiello LM, Ferrara N, King GL. 1994. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487.
3. Bamforth SD, Lightman S, Greenwood J. 1996. The effect of TNF-alpha and IL-6 on the permeability of the rat blood-retinal barrier in vivo. Acta Neuropath 91:624-632.
4. Bamforth SD, Lightman SL, Greenwood J. 1997a. Interleukin-β-induced disruption of the retinal vascular barrier of the central nervous system is mediated through leukocyte recruitment and histamine. Am J Pathol 150:329-340.
5. Bamforth SD, Lightman SL, Greenwood J. 1997b. Ultrastructural analysis of interleukin-1 beta-induced leukocyte recruitment to the rat retina. Invest Ophthalmol Vis Sci 38:25-35.
6. Bazan NG. 1989. Metabolism of arachidonic acid in the retina and retinal pigment epithelium: Biological effects of oxygenated metabolites of arachidonic acid. Prog Clin Biol Res 312:15-37.
7. Ben-Av P, Crofford LJ, Wilder RL, T H. 1995. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis. FEBS Lett 372:83-87.
8. Bermont L, Lamielle F, Fauconnet S, Esumi H, Weisz A, Adessi GL. 2000. Regulation of vascular endothelial growth factor expression by insulin-like growth factor-1. Int J Cancer 85:117-123.
9. Bold G, Altmann K-H, Bruggen J, Frei J, Lang M, Manley PW, Traxler P, Wietfeld B, Buchdunger E, Cozens R, Ferrari S, Furet P, Hofmann F, Martiny-Baron G, Mestan J, Rosel J, Sills M, Stover D, Acemonglu F, Boss E, Emmengger R, Lasser L, Masso E, R R, Schlachter C, Vetterli W, Wyss D, Wood JM. 2000. New anilino-phthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor driven angiogenesis. J Med Chem 43:2310-2323.
10. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. 2000. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145.
11. Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM. 1998. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci 39:581-591.
12. Claudio L, Martiney JA, Brosnan CF. 1994. Ultrastructural studies of the blood-retinal barrier after exposure to interleukin-1 beta or tumor necrosis factor-alpha. Lab Invest 70:850-861.
13. Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Insel PA, Messing RO. 2000. Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol 279:L429-L438.
14. Derevjanik NL, Vinores SA, Xiao W-H, Mori K, Turon T, Hudish T, Dong S, Campochiaro PA. 2002. Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci 43:2462-2467.
15. Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M, Wood J, Martiny-Baron G, Unger C, Marme D. 2000. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60:4819-4824.
16. Fabbro D, Buchdunger E, Wood J, Mestan J, Hofmann F, Ferrari S, Mett H, O'Reilly T, Meyer T. 1999. CGP 41251 a protein kinase inhibitor with potential as an anti-cancer agent. Pharmacol Ther 82:293-298.
17. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O'Reilly T, Meyer T. 2000. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15:17-28.
18. Ferrick MR, Thurau SR, Opppenheim MH, Herbort CP, Ming N, Zachariae COC, Matsushima K, Chan C-C. 1991. Ocular inflammation stimulated by intravitreal interleukin-8 and interleukin-1. Invest Ophthalmol Vis Sci 32:1534-1539.
19. Flach AJ, Dolan BJ, Irvine AR. 1987. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol 103:479-486.
20. Flach AJ, Stegman RC, Graham J, Druger LP. 1990. Prophylaxis of aphakic cystoid macular edema without corticosteroids. A paired-comparison, placebo-controlled double-masked study. Ophthalmology 97:1253-1258.
21. Goad DL, Rubin J, Wang H, Tashjian AHJ, Patterson C. 1996. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 137:2262-2268.
22. Harada S, Nagy JA, Sullivan KA, Thomas KA, Endo N, Rodan GA, Rodan SB. 1994. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest 93:2490-2496.
23. Hempel A, Maasch C, Heintze U, Lindschau C, Dietz R, Luft FC, Haller H. 1997. High glucose concentration increase endothelial cell permeability via activation of protein kinase C-alpha. Circ Res 81:363-371.
24. Kent KC, Mii S, Harrington EO, Chang JD, Mallette S, Ware JA. 1995. Requirement for protein kinase C activation in basic fibroblast growth factor-induced human endothelial cell proliferation. Circ Res 77:231-238.
25. Kent D, Vinores SA, Campochiaro PA. 2000. Macular oedema: The role of soluble mediators. Br J Ophthalmol 84:542-545.
26. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. 1984. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520-526.
27. Luna JD, Chan CC, Derevjanik NL, Mahlow J, Chiu C, Peng B, Tobe T, Campochiaro PA, Vinores SA. 1997. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: Comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J Neurosci Res 49:268-280.
28. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B, Yeo T-K, Yeo K-T. 1994. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145:574-584.
29. Mishima H, Masuda K, K M. 1989. The putative role of prostaglandins in cystoid macular edema. Alan R. Liss, Inc.
30. Miyake K. 1978. Prophylaxis of aphakic cystoid macular edema using topical indomethacin. J Am Intraocul Implant Soc 4:174-179.
31. Miyake K. 1984. Indomethacin in the treatment of postoperative cystoid macular edema. Surv Ophthalmol 28:554-568.
32. Mori K, Duh E, Gehlbach P, Ando A, Takahashi K, Pearlman J, Mori K, Yang HS, Zack DJ, Ettyreddy D, Brough DE, Wei LL, Campochiaro PA. 2001. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 188:253-263.
33. Neufeld AH, Sears ML. 1973. The site of action of prostaglandin E2 on the disruption of the blood-aqueous barrier in the rabbit eye. Exp Eye Res 17:445-448.
34. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K. 1997. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 64:505-517.
35. Patz A, Schatz H, Berkow JW, Gittelsohn AM, Ticho U. 1973. Macular edema: An overlooked complication of diabetic retinopathy. Trans Am Acad Ophthalmol Otolaryngol 77:34-42.
36. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LEH. 1995. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92:905-909.
37. Punglia RS, Lu M, Hsu J, Kuroki M, Tolentino MJ, Keough K, Levy AP, Levy NS, Goldberg MA, D'Amato RJ, Adamis AP. 1997. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 46:1619-1626.
38. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancoupoulos GD, Adamis AP. 2001. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:2408-2413.
39. Rothova A, Suttorp-vanSchulten MSA, Treffers WF, Kijlstra A. 1996. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80:332-336.
40. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K, Kuwano M. 1996. Induction of vascular endothelial growth factor by tumor necrosis factor-alpha in human glioma cells. J Biol Chem 271:28220-28228.
41. Shapiro SS, Wilk MB. 1965. An analysis of variance test for normality (complete samples). Biometrika 52:591-611.
42. Siflinger-Birnboim A, Goligorsky MS, Del Vecchio PJ, Malik AB. 1992. Activation of protein kinase C pathway contributes to hydrogen peroxide-induced increase in endothelial permeability. Lab Invest 67:24-30.
43. Strawn SM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK. 1996. Flk-1 as a target for tumor growth inhibition. Cancer Res 56:3540-3545.
44. The Branch Vein Occlusion Study Group. 1984. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98:271-282.
45. The Central Vein Occlusion Study Group Report. 1995. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology 102:1425-1433.
46. Vegge T, Neufeld AH, Sears ML. 1975. Morphology of the breakdown of the blood-aqueous barrier in the ciliary processes of the rabbit eye after prostaglandin E2. Invest Ophthalmol Vis Sci 14:33-36.
47. Verbeke G, Molenberghs G. 2000. Linear mixed models for longitudinal data. New York: Springer-Verlag, Inc.
48. Vinores SA, Sen H, Campochiaro PA. 1992. An adenosine agonist and prostaglandin E1 cause breakdown of blood-retinal barrier by opening tight junctions between vascular endothelial cells. Invest Ophthalmol Vis Sci 33:1870-1878.
49. Vinores SA, Küchle M, Mahlow J, Chiu C, Green WR, Campochiaro PA. 1995. Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/ vascular permeability factor. Am J Pathol 147:1289-1297.
50. Vinores SA, Youssri AI, Luna JD, Chen Y-S, Bhargave S, Vinores MA, Schoenfeld C-L, Peng B, Chan C-C, LaRochelle W, Green WR, Campochiaro PA. 1997. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol 12:99-109.
51. Vinores SA, Chan C-C, Vinores MA, Matteson DM, Chen Y-S, Klein DA, Shi A, Ozaki H, Campochiaro PA. 1998. Increased vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-beta) in experimental autoimmune uveoretinitis: Upregulation of VEGF without neovascularization. J Neuroimmunol 89:43-50.
52. Vuong PT, Malik AB, Nagpala PG, Lum H. 1998. Protein kinase C beta modulates thrombin-induced Ca2+ Signaling and endothelial permeability increase. J Cell Physiol 175:379-387.
53. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB. 1996. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 271:29483-29488.
54. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H. 1997. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17:4015-4023.